Cell Division Cycle 7 Related Protein Kinase – Pipeline Review, H2 2019

Global Markets Direct’s, 'Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)- Pipeline Review, H2 2019’, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

– The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eli Lilly and Co

Lin Bioscience Inc

Millennium Pharmaceuticals Inc

NMS Group SpA

Sierra Oncology Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Overview

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Companies Involved in Therapeutics Development

Eli Lilly and Co

Lin Bioscience Inc

Millennium Pharmaceuticals Inc

NMS Group SpA

Sierra Oncology Inc

Takeda Pharmaceutical Co Ltd

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Drug Profiles

LBS-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143921 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSK-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simurosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDC7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRA-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Dormant Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Discontinued Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Apr 03, 2019: Sierra reports late-breaking SRA141 preclinical data in poster at AACR 2019

Feb 27, 2019: Sierra Oncology announces late-breaking poster presentation at AACR 2019 for SRA141 preclinical data

Nov 13, 2018: Sierra Oncology reports SRA141 preclinical efficacy at EORTC-NCI-AACR symposium

Nov 09, 2018: Successful Completion of IND filing with FDA for SRA141

Apr 24, 2018: Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia

Feb 27, 2018: Sierra Oncology Provides Update on SRA141

Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York

Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Lin Bioscience Inc, H2 2019

Pipeline by Millennium Pharmaceuticals Inc, H2 2019

Pipeline by NMS Group SpA, H2 2019

Pipeline by Sierra Oncology Inc, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports